Barclays analyst Peter Lawson maintained a Buy rating on Epizyme (EPZM – Research Report) on January 13 and set a price target of $4.00. The company's shares closed last Friday at $2.17, close to its 52-week low of $2.16. According to TipRanks.com, Lawson is a 3-star analyst with an average return of 4.2% and a 43.3% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Karyopharm Therapeutics, and Prelude Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $10.33 average price target.
https://www.tipranks.com/news/blurbs/epizyme-epzm-receives-a-buy-from-barclays?utm_source=advfn.com&utm_medium=referral
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Epizyme Charts.
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Epizyme Charts.